(Total Views: 511)
Posted On: 08/17/2020 12:43:44 PM
Post# of 653
$RLFTF Yaybar DD (copy) This. Is. It.
This was the original study of RLF 100 in the setting of ARDS and sepsis performed in 1999 but was not published.
https://assets.researchsquare.com/files/rs-52...c244ee.pdf
COVID 19 infection and its effect causing illness/death is due to “Cytokine storm” which in mild to moderate cases causes hospitalization and in severe case leads to ICU level of care due to ARDS and eventually leads to death.
This trial data was a reason enough for FDA to approve phase 2/3 trial for RLF 100.
If the data from Dr Youssef from Houston Methodist this week shows similar response as noted earlier this month, then the therapeutic effect of RLF 100 will not be accounted by any placebo effect.
Game changer for stock price: Trial for RLF 100 now includes the majority of hospitalized COVID 19 patients.
It will replace Remdesevir as a drug of choice which is now given to every hospitalized patients with low oxygen saturation (lowest threshold to start the medication)
Inhalation RLF: Relief is the one with inhalation approved formulary of VIP.
It will take minimum 2 years even for big pharmas to go through the process of preliminary approval to start human trial. If IV infusion of RLF 100 works, inhaled RLF 100 can be used concurrently in hospitalized patients to increase therapeutic effect and decrease side effects.
Use in the outpatient settings/milder cases all over the world will be in hundreds of millions.
FDA approval: Mid October
Will only happen after the randomized trial result is out. Enrollments should be done by the 15th of September per Dr Javits’s interview with Dr Yo. Trial will run for 2 weeks after last enrollment. Data processing and review will take another 2 weeks. By mid-October FDA will have the data and decision will be made.
The world can then take a deep breath of Relief.
This was the original study of RLF 100 in the setting of ARDS and sepsis performed in 1999 but was not published.
https://assets.researchsquare.com/files/rs-52...c244ee.pdf
COVID 19 infection and its effect causing illness/death is due to “Cytokine storm” which in mild to moderate cases causes hospitalization and in severe case leads to ICU level of care due to ARDS and eventually leads to death.
This trial data was a reason enough for FDA to approve phase 2/3 trial for RLF 100.
If the data from Dr Youssef from Houston Methodist this week shows similar response as noted earlier this month, then the therapeutic effect of RLF 100 will not be accounted by any placebo effect.
Game changer for stock price: Trial for RLF 100 now includes the majority of hospitalized COVID 19 patients.
It will replace Remdesevir as a drug of choice which is now given to every hospitalized patients with low oxygen saturation (lowest threshold to start the medication)
Inhalation RLF: Relief is the one with inhalation approved formulary of VIP.
It will take minimum 2 years even for big pharmas to go through the process of preliminary approval to start human trial. If IV infusion of RLF 100 works, inhaled RLF 100 can be used concurrently in hospitalized patients to increase therapeutic effect and decrease side effects.
Use in the outpatient settings/milder cases all over the world will be in hundreds of millions.
FDA approval: Mid October
Will only happen after the randomized trial result is out. Enrollments should be done by the 15th of September per Dr Javits’s interview with Dr Yo. Trial will run for 2 weeks after last enrollment. Data processing and review will take another 2 weeks. By mid-October FDA will have the data and decision will be made.
The world can then take a deep breath of Relief.
(0)
(0)
$MJ
